by The U.S. circulating tumor cells market size was valued at USD 4.48 billion in 2023 and is anticipated to reach around USD 14.93 billion by 2033, growing at a CAGR of 12.79% from 2024 to 2033.
Key Pointers
- By Specimen, the blood segment held the largest revenue share of 48% in 2023.
- By Specimen, the body fluids predicted to grow at the remarkable CAGR of from 2024 to 2033.
- By Technology, the CTC enrichment methods segment dominated the market with a share of 67% in 2023.
- By Technology, the CTC analysis segment is forecasted to experience the highest compound annual growth rate (CAGR) from 2024 to 2033.
- By Application, the research segment commanded the largest market share at 75% in 2023.
- By Product, the kits & reagents segment led the market with a share of 45% in 2023.
- By Product, the devices or systems segment is forecasted to experience the highest compound annual growth rate (CAGR) from 2024 to 2033.
Get a Sample@ https://www.visionresearchreports.com/report/sample/41271
Introduction to Circulating Tumor Cells (CTCs)
Circulating tumor cells (CTCs) are cancer cells that have detached from the primary tumor and entered the bloodstream. These cells have the potential to spread to other parts of the body, leading to metastasis, which is a major cause of cancer-related deaths. Studying CTCs can provide valuable insights into the biology of cancer and help in the development of targeted therapies.
Understanding the U.S. Circulating Tumor Cells Market
The U.S. circulating tumor cells market is characterized by a high level of innovation and competition. With the rising incidence of cancer and the growing demand for non-invasive diagnostic tools, the market for CTC analysis is expected to witness significant growth in the coming years. Factors such as technological advancements, increasing research funding, and rising healthcare expenditure are driving market growth.
Technological Advancements in CTC Detection
Recent years have seen significant advancements in the detection and analysis of CTCs. Technologies such as liquid biopsy, microfluidics, and immunomagnetic separation have revolutionized the field of CTC research, allowing for the detection and characterization of rare cancer cells with high sensitivity and specificity.
Applications of CTC Analysis
Early Cancer Detection:
CTC analysis holds promise as a non-invasive method for early cancer detection. By capturing and analyzing CTCs in blood samples, healthcare providers can identify the presence of cancer cells before symptoms manifest or conventional imaging techniques detect tumors. Early detection enables prompt intervention and improves treatment outcomes.
Monitoring Treatment Response:
CTC analysis plays a crucial role in monitoring the effectiveness of cancer treatments, such as chemotherapy, targeted therapy, and immunotherapy. Changes in CTC counts or characteristics during treatment can indicate treatment response or resistance, guiding adjustments to therapy regimens for better patient outcomes.
Minimal Residual Disease Detection:
After primary tumor resection or completion of treatment, CTC analysis helps identify minimal residual disease (MRD), which refers to small amounts of cancer cells that may remain in the body undetected. Detecting MRD early allows healthcare providers to intervene promptly and prevent disease recurrence.
Prognostic Evaluation:
The presence and characteristics of CTCs serve as prognostic markers for assessing disease progression and predicting patient outcomes. High CTC counts or specific molecular profiles of CTCs may indicate a poorer prognosis, prompting more aggressive treatment strategies or closer monitoring of patients at higher risk of disease recurrence.
Personalized Treatment Selection:
CTC analysis facilitates personalized treatment selection by identifying actionable molecular targets or drug resistance mechanisms present in CTCs. This information enables healthcare providers to tailor treatment regimens to individual patients, maximizing therapeutic efficacy while minimizing adverse effects.
Cancer Research:
CTC analysis contributes to advancing cancer research by providing researchers with valuable samples for studying tumor biology, metastasis, and drug resistance mechanisms. By analyzing CTCs collected from patients, researchers gain insights into the underlying mechanisms driving cancer progression and develop novel therapeutic strategies.
Clinical Trials:
CTC analysis plays a vital role in clinical trial enrollment and monitoring. By assessing CTC counts and molecular characteristics, researchers can identify eligible patients, stratify participants based on prognosis or treatment response, and evaluate the efficacy of investigational therapies in real-time, accelerating the development of new cancer treatments.
Read More: https://www.heathcareinsights.com/oncology-companion-diagnostic-market/
U.S. Circulating Tumor Cells Market Key Companies
- QIAGEN
- Bio-Techne Corporation
- Precision for Medicine
- AVIVA Biosciences
- BIOCEPT, Inc.
- BioCEP Ltd.
- Fluxion Biosciences, Inc.
- Greiner Bio-One International GmbH
- Ikonisys, Inc.
- Miltenyi Biotec
- IVDiagnostics, Inc.
- BioFluidica
- Canopus Bioscience Ltd.
- Biolidics Limited
- Creativ MicroTech, Inc.
- LungLife AI, Inc.
- Epic Sciences
- Rarecells Diagnostics
- ScreenCell
- Menarini Silicon Biosystems
- LineaRx, Inc. (Vitatex, Inc.)
- Sysmex Corporation
- STEMCELL Technologies, Inc.
Recent Developments
- In February 2024, BioXcel Therapeutics, Inc. received Fast Track Designation from the U.S. FDA for BXCL701. This investigational, oral innate immune activator is designed to induce inflammation in the tumor microenvironment.
- In August 2023, Cell Microsystems acquired Fluxion Biosciences, Inc. This acquisition complements Cell Microsystems’ CellRaft technology-based platforms and applications, allowing for the development of innovative cell analysis solutions.
- In February 2022, Epic Sciences entered into a collaboration with Fulgent Genetics. This collaboration aims to integrate DefineMBC results into Fulgent’s existing testing portfolio, enhancing accessibility for healthcare providers and metastatic breast cancer (MBC) patients.
U.S. Circulating Tumor Cells Market Segmentations:
By Technology
- CTC Detection & Enrichment Methods
- Immunocapture (Label-based)
- Positive Selection
- Negative Selection
- Size-based Separation (Label-free)
- Membrane-based
- Microfluidic-based
- Density-based Separation (Label-free)
- Combined Methods
- Immunocapture (Label-based)
- CTC Direct Detection Methods
- SERS
- Microscopy
- Others
- CTC Analysis
By Application
- Clinical/ Liquid Biopsy
- Risk Assessment
- Screening and Monitoring
- Research
- Cancer Stem Cell & Tumorogenesis Research
- Drug/Therapy Development
By Product
- Kits & Reagents
- Blood Collection Tubes
- Devices or Systems
By Specimen
- Blood
- Bone Marrow
- Other Body Fluids
Buy this Premium Research Report@ https://www.visionresearchreports.com/report/checkout/41271
You can place an order or ask any questions, please feel free to contact sales@visionresearchreports.com| +1 650-460-3308
